Adani Wilmar, may be all set to become the seventh Adani group company to list on the bourses. Adani Wilmar has filed the draft red herring prospectus (DRHP) with SEBI for a proposed Rs.4,500 crore IPO. The finer details of the IPO are yet to be fina

Investors who have applied for Glenmark Life Sciences IPO are very keen to know if the IPO is being allotted to them. Allotment of shares happens based on rules prescribed by the regulatory body i.e. SEBI. Allocation is categorised as retail investor

The Indian equity markets started the week on a positive note on account of positive global sentiments. In addition, the news that GST collection recovered to a three-month high in July, above Rs1 lakh crore mark, as economic activity restarted also

The next big story in the auto space appears to be electrical vehicles. Just last week, the chairman of Tata Sons announced a $3-4 billion investment in FY22 in the EV business. The other major CV manufacturer, Ashok Leyland, is not too far behind. O

After a rather tepid June month due to COVID 2.0 lag effect, the sales of automobiles picked up sharply in July. With auto factories and showrooms functioning at near-normal capacity, the bounce was on the cards. Let us look at two major listed PV ma

For the week starting 02 August, there are a total of 4 IPOs lined up with all the 4 IPOs opening for subscription on 04 August and closing on 06 August. What you need to know about the 4 IPOs? Here is a gist of the 4 IPOs slated to tap t

As part of its risk management system, NSE issued a circular on 31 July highlighting the logic for quantity freeze and the respective quantity freeze limits for the 3 indices traded in F&O viz. Nifty, Bank Nifty and Nifty Financial Services index

As per the latest data put out by Praxis, the Indian IPO market saw new issues collecting Rs.27,052 crore in the first four months. Considering that another Rs.70,000 crore of IPOs are lined for FY22, this could end up being a record year for IPO col

Windlas Biotech is a key player in the CDMO (contract development & manufacturing organization), is a specialized activity wherein a pharma company offers the niche service of additional manufacturing capacity or even specialized research service

Supriya Lifesciences, a manufacturer of active pharma ingredients (APIs) has filed the draft red herring prospectus (DRHP) with SEBI for its proposed IPO. The company is planning to raise Rs.1,200 crore from the primary market, which will include a f

Aptus value Housing caters to the fast growing low-to-mid end customers with a predominant focus on the self-employed segment. Despite this focus on the volatile self-employed segment, Aptus has managed to keep the gross NPAs under check. Here is a q

Ami Organics has already filed the draft red herring prospectus with SEBI for its proposed public issue of shares. The company is into the fast growing and lucrative specialty chemicals space and has seen rapid growth in the last few years. Also, glo